Eli Lilly faces more claims over diabetes treatment
A French company has brought additional claims of US$200 million against US pharmaceuticals giant Eli Lilly in an ICC arbitration begun last year over a collaborative research project to develop an insulin treatment for diabetes.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10